This report presents a strategic analysis of the APAC ENT Devices Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the APAC ENT Devices Market, offering unmatched value, accuracy and expert insights.
As of December 2016, third-party payer insurance coverage for standalone balloon sinus dilation procedures is available for an estimated 230 million people in the US, which represents 80% of the covered people in the country. In the US, the standalone balloon sinus dilation procedure performed at the physician’s office is covered by various third-party payers, such as Medicare, United Healthcare, Aetna, Cigna, Humana, Kaiser Permanente, TRICARE, Health Net, Medicaid, Blue Cross Blue Shield. Also, coverage of USD 180-USD 300 is provided for throat procedures such as tonsillectomies. For instance, the reimbursement for the tonsillectomy procedure within the state of Virginia is USD 200 (including follow-up care for 90 days after the procedure). Thus, a favorable reimbursement scenario in developed countries provides the impetus for the growth of the ENT devices market.
The APAC ENT Device Market size is at around US $ xx Bn in 2021 and is projected to reach US $ xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period.
APAC ENT Device Market Size (In USD Bn)
(2021-2030F)
Market Growth Drivers Analysis
For market participants in ENT devices, emerging markets like China, India, and LATAM (Latin American) nations provide considerable growth prospects. The OECD projects that by 2030, there will be 4.9 billion middle-class people worldwide, up from 1.8 billion in 2009. By 2030, it is anticipated that 66% of the world's middle-class people will reside in Asia. People in developing nations like China and India are now able to buy ENT devices with cutting-edge technology, which is boosting the market's expansion.
Furthermore, a number of prospects for the expansion of this market exist in emerging nations due to factors like laxer regulatory standards, growing urbanization, better healthcare facilities, rising disposable income, and an ageing older population. Several industry players are concentrating on increasing their market presence in developing countries in order to take advantage of the potential opportunities in the ENT devices market. In this regard, Intersect ENT received CE Mark approval for PROPEL Contour in May 2021 for patients who had frontal sinus surgery and developed chronic rhinosinusitis. If these items are approved, market participants will be able to expand their product offers in developing areas. Emerging economies throughout the forecast period create new income pockets for market competitors due to the aforementioned causes.
Market Restraints
Reducing healthcare costs has become one of the main priorities for healthcare systems during the past ten years. This is accomplished through the implementation of price controls, competitive pricing, bidding, tender mechanics, coverage and payment policies, the relative efficacy of therapies, technology assessments, and managed-care agreements. Healthcare providers have allied themselves with group purchasing organizations and integrated health networks that bargain for the bulk purchase of medical devices in response to mounting pressure to lower healthcare costs. The tendency toward bulk purchasing puts more pressure on prices and reduces players' profit margins, especially for small- and medium-sized producers who have a constrained selection of ENT devices.
Key Players
The prominent players operating in this market include Karl Storz Gmbh & co. KG (Germany), Medtronic plc (Ireland), Stryker Corporation (US), Smith & Nephew plc (UK), Olympus Corporation (Japan), Acclarent, inc. (a subsidiary of Johnson & Johnson) (US), Cochlear Limited (Australia), Hoya Corporation (Japan), GN Store Nord (Denmark), Welch Allyn (Hill-Rom Holding Inc.) (Denmark), etc.
1. Executive Summary
1.1 Device Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Regulatory Landscape for Medical Device
1.6 Health Insurance Coverage in Country
1.7 Type of Medical Device
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
The ENT Device Market is segmented as mentioned below:
By Product Type (Revenue, USD Billion):
By Diagnostic Devices (Revenue, USD Billion):
By Surgical Device (Revenue, USD Billion):
By End Users (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.